Efficacy and safety of nituzumab combined with albumin bound paclitaxel in treatment of pancreatic cancer

doi:10.3877/cma.j.issn.1674-0785.2023.04.008

Abstract

Abstract:

Objective

To evaluate the safety and efficacy of nituzumab combined with albumin bound paclitaxel in the treatment of pancreatic cancer.

Methods

Ninety-six pancreatic cancer patients hospitalized at Affiliated Central Hospital of Jiangnan University from February 16, 2018 to December 16, 2021 were randomly and evenly divided into a control group (48 cases) and a combination group (48 cases) according to odd and even numbers. The control group was treated with albumin bound paclitaxel alone, and the combination group was treated with nituzumab combined with albumin bound paclitaxel. The treatment effect, disease control rate, serum tumor markers (CA19-9, CA125, CA50, and CEA), pain degree (VAS), survival rate, and safety evaluation (adverse reaction rate) were compared between the two groups before and after treatment.

Results

The effective rate (60.42%) and disease control rate (75.00%) of the combination group were significantly higher than those of the control group (39.58% and 52.08%, respectively; P＜0.05), while the incidence of nausea, vomiting, and myelosuppression in the combination group was significantly lower than that of the control group (P＜0.05). Although there was no significant difference in the levels of CA19-9, CA125, CA50, and CEA between the two groups before treatment (P＞0.05), all of them decreased significantly in both groups after treatment, and were significantly lower in the combination group than in the control group (P＜0.05). There was no significant difference in VAS score between the two groups before treatment (P＞0.05), but VAS score decreased significantly in both groups after treatment and was significantly lower in the combination group than in the control group (P＜0.05). There was no significant difference in the survival rate between the two groups at 3, 6, and 9 months after treatment (P＞0.05), but the survival rate at 12 months after treatment was significantly higher in the combination group than in the control group (P＜0.05).

Conclusion

For patients with pancreatic cancer, the combination of nifetazumab and albumin bound paclitaxel is significantly more effective than albumin bound paclitaxel alone, which can reduce the levels of tumor markers, reduce patients' pain, and improve survival rate and safety.

Key words: Nitozumab, Albumin bound paclitaxel, Pancreatic cancer, Safety, Effectiveness

Wenxi Cao, Xiao Chen, Laifa Zhu, Yongping Zhou. Efficacy and safety of nituzumab combined with albumin bound paclitaxel in treatment of pancreatic cancer[J]. Chinese Journal of Clinicians(Electronic Edition), 2023, 17(04): 409-413.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhlcyszz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-0785.2023.04.008

https://zhlcyszz.cma-cmc.com.cn/EN/Y2023/V17/I04/409

Figures/Tables 6

组别	例数	年龄（岁， $x ¯$ ±s）	性别［例（%）］		肿瘤部位［例（%）］
组别	例数	年龄（岁， $x ¯$ ±s）	男性	女性	胰头	胰体尾	弥漫或多灶
对照组	48	55.52±9.17	27（56.25）	21（43.75）	19（39.58）	27（56.25）	2（4.17）
联合组	48	57.82±8.58	30（62.50）	18（37.50）	23（47.92）	23（47.92）	2（4.17）
t/χ²值		1.269	0.389		0.701
P值		0.208	0.533		0.704

组别	例数	年龄（岁， $x ¯$ ±s）	性别［例（%）］		肿瘤部位［例（%）］
组别	例数	年龄（岁， $x ¯$ ±s）	男性	女性	胰头	胰体尾	弥漫或多灶
对照组	48	55.52±9.17	27（56.25）	21（43.75）	19（39.58）	27（56.25）	2（4.17）
联合组	48	57.82±8.58	30（62.50）	18（37.50）	23（47.92）	23（47.92）	2（4.17）
t/χ²值		1.269	0.389		0.701
P值		0.208	0.533		0.704

组别	例数	显效	有效	一般	无效	总有效率	控制率
联合组	48	9（18.75）	20（41.67）	7（14.58）	12（25.00）	29（60.42）	36（75.00）
对照组	48	4（8.33）	15（31.25）	6（12.50）	23（47.92）	19（39.58）	25（52.08）
$χ 2$ 值						4.167	5.441
P值						0.041	0.020

组别	例数	显效	有效	一般	无效	总有效率	控制率
联合组	48	9（18.75）	20（41.67）	7（14.58）	12（25.00）	29（60.42）	36（75.00）
对照组	48	4（8.33）	15（31.25）	6（12.50）	23（47.92）	19（39.58）	25（52.08）
$χ 2$ 值						4.167	5.441
P值						0.041	0.020

时间	例数	CA19-9（U/ml）	CA125（U/ml）	CA50（U/ml）	CEA（ng/ml）
治疗前
联合组	48	83.19±10.55	79.38±11.25	56.57±9.21	27.11±7.21
对照组	48	81.88±11.27	81.47±10.47	58.10±9.54	25.95±7.42
t值		0.588	0.942	0.799	0.777
P值		0.558	0.349	0.426	0.439
治疗后
联合组	48	26.12±7.45^a	28.11±5.77^a	25.12±6.04^a	6.01±2.23^a
对照组	48	35.47±8.05^a	38.24±6.23^a	31.55±7.43^a	9.44±3.11^a
t值		5.906	8.265	4.652	6.210
P值		＜0.001	＜0.001	＜0.001	＜0.001

组别	例数	治疗前	治疗后	t值	P值
联合组	48	7.55±1.82	3.34±0.59	15.245	＜0.001
对照组	48	7.29±2.04	5.42±1.01	5.691	＜0.001
t值		0.659	12.320
P值		0.512	＜0.001

组别	例数	生存率
组别	例数	治疗后3个月	治疗后6个月	治疗后9个月	治疗后12个月
联合组	48	44（91.67）	39（81.25）	34（70.83）	31（64.58）
对照组	48	43（89.58）	38（79.16）	26（54.16）	17（35.42）
$χ 2$ 值		0.123	0.066	2.844	8.167
P值		0.726	0.798	0.092	0.004

组别	例数	生存率
组别	例数	治疗后3个月	治疗后6个月	治疗后9个月	治疗后12个月
联合组	48	44（91.67）	39（81.25）	34（70.83）	31（64.58）
对照组	48	43（89.58）	38（79.16）	26（54.16）	17（35.42）
$χ 2$ 值		0.123	0.066	2.844	8.167
P值		0.726	0.798	0.092	0.004

组别	例数	腹泻乏力	黏膜反应	骨髓抑制	恶心呕吐
联合组	48	15（31.25）	15（31.25）	5（10.42）	3（6.25）
对照组	48	12（25.00）	17（35.42）	14（29.17）	15（31.25）
$χ 2$ 值		0.464	0.188	5.315	9.846
P值		0.496	0.665	0.021	0.002

组别	例数	腹泻乏力	黏膜反应	骨髓抑制	恶心呕吐
联合组	48	15（31.25）	15（31.25）	5（10.42）	3（6.25）
对照组	48	12（25.00）	17（35.42）	14（29.17）	15（31.25）
$χ 2$ 值		0.464	0.188	5.315	9.846
P值		0.496	0.665	0.021	0.002

References 19

1	孙路遥, 尹梦媛, 谢克平, 等. 肿瘤相关成纤维细胞在胰腺癌发生发展中的研究进展 [J].肿瘤学杂志, 2021, 27(2): 95-104.
2	Tonini V, Zanni M. Pancreatic cancer in 2021: What you need to know to win [J]. World J Gastroenterol, 2021, 27(35): 5851-5889.
3	吕伟, 刘一娇, 邬丹莲, 等. 白蛋白结合型紫杉醇用于多种实体肿瘤治疗的卫生技术评估 [J/OL]. 今日药学: 1-15.
4	毛雨秋, 陈良峰, 韩菲菲. 尼妥珠单抗联合GS化疗治疗晚期胰腺癌患者临床研究 [J]. 中国合理用药探索, 2019, 16(10): 29-31.
5	祁娟, 郭伟华, 段仁慧. 白蛋白结合型紫杉醇联合吉西他滨与吉西他滨单药治疗晚期胰腺癌的疗效及安全性 [J]. 新疆医学, 2022, 52(10): 1165-1167+1178.
6	王尧, 钟国成, 李迎春, 等. 尼妥珠单抗联合盐酸吉西他滨治疗高表达表皮生长因子受体中晚期胰腺癌患者的临床研究 [J]. 成都医学院学报, 2020, 15(5): 615-618.
7	韩春, 叶斯斯, 李娟, 等. 尼妥珠单抗联合吉西他滨一线治疗晚期胰腺癌的疗效观察 [J].解放军医学院学报, 2021, 42(6): 596-600+614.
8	Han SY, Kim DU, Seol YM, et al. Comparison of gemcitabine plus nab-paclitaxel and FOLFIRINOX in metastatic pancreatic cancer [J]. World J Clin Cases, 2020, 8(17): 3718-3729.
9	Zuzčák M, Trnka J. Cellular metabolism in pancreatic cancer as a tool for prognosis and treatment (Review) [J]. Int J Oncol, 2022, 61(2): 93.
10	Klein AP. Pancreatic cancer epidemiology: understanding the role of lifestyle and inherited risk factors [J]. Nat Rev Gastroenterol Hepatol, 2021, 18(7): 493-502.
11	李惠, 曹永春, 于拥军, 等. FNDC5/Irisin、NEDD9在胰腺癌组织中的表达及给予白蛋白结合型紫杉醇联合吉西他滨治疗的预后观察 [J]. 临床医学工程, 2022, 29(11): 1493-1494.
12	张伟, 姜卫, 武凯龙, 等. 同步放化疗和尼妥珠单抗联合放疗治疗老年晚期鼻咽癌的疗效对比分析 [J]. 中国肿瘤临床与康复, 2022, 29(4): 425-427.
13	Tian Z, Yao W. Albumin-bound paclitaxel: worthy of further study in sarcomas [J]. Front Oncol, 2022, 12: 815900.
14	Sato T, Okazaki M, Sano J, et al. Binding affinities of paclitaxel and docetaxel for generic and nanoparticle albumin-bound paclitaxel-derived albumin from human serum [J]. Biomed Rep, 2021, 14(4): 35.
15	Lv ZD, Song HM, Niu ZH, et al. Efficacy and safety of albumin-bound paclitaxel compared to docetaxel as neoadjuvant chemotherapy for HER2-negative breast cancer [J]. Front Oncol, 2022, 11: 760655.
16	Abourehab MAS, Alqahtani AM, Youssif BGM, et al. Globally approved EGFR inhibitors: insights into their syntheses, target kinases, biological activities, receptor interactions, and metabolism [J]. Molecules, 2021, 26(21): 6677.
17	Yuan Y, Chen J, Fang M,et al. Nimotuzumab combined with chemoradiotherapy for the treatment of cervical cancer: A meta-analysis of randomized controlled trials [J]. Front Oncol, 2022, 12: 994726.
18	潘琦, 忻笑. 白蛋白结合型紫杉醇治疗晚期胰腺癌患者的护理体会 [J]. 上海护理, 2020, 20(9): 53-55.
19	马艳荣, 赵莉, 王永增, 等. 尼妥珠单抗联合吉西他滨和替吉奥方案用于晚期胰腺癌的疗效观察及对癌组织中E钙黏蛋白和β-连环蛋白表达的影响 [J]. 中国医药, 2021, 16(10): 1480-1484.

[1]	Jinglong He, Hongxi Shang, Min Hao, Wei Xie, Minghong Gao, Wei Sun, Anqing Liu. Clinical effect of multiple joints replacements in patients with severe rheumatoid arthritis [J]. Chinese Journal of Joint Surgery(Electronic Edition), 2023, 17(06): 860-864.
[2]	Peizhong Shang, Runping Zhang, Wei Zhang, Guohong Jia, Xiaowu Li, Jianjun Miao, Bing Liu. Clinical application of novel techniques for obstructive jaundice prevention and treatment: a single-center study [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(01): 104-107.
[3]	Bo Mo, Pei Wang, Heng Wang, Zhijun He, Jun Liang, Zhinan Hao. Curative effect of laparoscopic radical gastrectomy and modified radical gastrectomy for early gastric cancer [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2023, 17(06): 644-647.
[4]	Duojie Suolang, Hongqiao Gao, Dunzhu Basang, Sang Ren. Clinical analysis of different laparoscopic procedures in the treatment of hepatic cystic echinococcosis in Tibet [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2023, 17(06): 670-673.
[5]	Haiqin Tang, Xiuzhi Guo, Xiaosu Zhu, Shidi Zhao. Clinical safety study of "tunnel method" laparoscopic anatomic left hemihepatectomy [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2023, 17(06): 674-677.
[6]	Hao Tang, Ping Liang, Xiaojiang Xu, Kai Zeng, Pohui Wen. The clinical studies of laparoscopic right hemihepatectomy with caudate lobectomy under the guidanceof three-dimensional reconstruction for Bismuth type Ⅲahilar cholangiocarcinoma [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2023, 17(06): 688-692.
[7]	Yi Wang, Sizhe Xu, Zhangxia Ren. Effect of endoscopic unilateral thyroid lobectomy via thoracic breast approach and open surgery on postoperative recovery in patients with differentiated thyroid cancer [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2023, 17(05): 542-545.
[8]	Weiqiang Fan, Shibu Lin, Chuanwei Sun, Qifeng Song, Wang Li, Yu Fu, Ai Chen. Clinical comparative analysis of Bismuth-Corlette Ⅲ and Ⅳ laparoscopic surgery for hilar cholangiocarcinoma with different resection scopes [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2023, 17(04): 423-426.
[9]	Jun Liu, Ji Zhu, Jun Yin. Anesthesia effect and safety of dexmedetomidine in inguinal hernia surgery [J]. Chinese Journal of Hernia and Abdominal Wall Surgery(Electronic Edition), 2023, 17(05): 570-573.
[10]	Hongmin Wang, Yunbo Xie, Yanhu Wang, Fusheng Wang. The advance of clinical research in mesenchymal stem cell treatment for COVID-19 [J]. Chinese Journal of Cell and Stem Cell(Electronic Edition), 2023, 13(04): 247-256.
[11]	Fengjie Wang, Liguang Wang, Shan Liao, Ying Liu, Rongdang Fu, Huanwei Chen. Safety and efficacy of laparoscopic right hemihepatectomy for hepatocellular carcinoma [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2023, 12(05): 517-522.
[12]	Heya Na, Dan Zhu. Effect of red-light therapy in myopia control in children [J]. Chinese Journal of Ophthalmologic Medicine(Electronic Edition), 2023, 13(04): 252-256.
[13]	Wenlong Liang, Jie Cao, Qing Huang, Yong Lin, Hongli Huang, Ping Yang, Guanwei Li, He Hu. Efficacy and safety analysis of sintilimab combined with regofenib in the treatment of advanced colorectal cancer [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2023, 13(06): 409-413.
[14]	Tingting Chen, Xueliang Jiang, Jiali Yu, Jianlin Ke. Safety of stem cells in the treatment of inflammatory bowel disease [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2023, 13(04): 193-198.
[15]	Jun Liang, Chenyu Chu, Fengyan Sun, Yilang Yuan, Xi Zhou, Weidong Wang. Feasibility and safety of reverse puncture with tunnel needle in totally implantable venous access port [J]. Chinese Journal of Interventional Radiology(Electronic Edition), 2023, 11(04): 310-313.

Please choose a citation manager

Content to export